2008
Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction
Chia S, Nagurney J, Brown D, Raffel O, Bamberg F, Senatore F, Wackers F, Jang I. Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. The American Journal Of Cardiology 2008, 103: 333-337. PMID: 19166685, DOI: 10.1016/j.amjcard.2008.09.085.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionPrimary PCIST-segment elevation myocardial infarctionElevation myocardial infarctionLarger infarct sizePercutaneous coronary interventionInfarct sizeNeutrophil countMyocardial infarctionElevated leukocytesLeukocyte countCardiac eventsCoronary interventionFirst ST-segment elevation myocardial infarctionAcute Myocardial Infarction StudyST-elevation myocardial infarctionAssociation of leukocytesComposite cardiac eventsIntracellular calcium modulatorsLeft Ventricular SalvageAdverse cardiac eventsElevated leukocyte countPlacebo-controlled trialMyocardial Infarction Study
2007
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)
Jang I, Weissman N, Picard M, Zile M, Pettigrew V, Shen S, Tatsuno J, Hibberd M, Tzivoni D, Wackers F, Investigators T. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). American Heart Journal 2007, 155: 113.e1-113.e8. PMID: 18082500, DOI: 10.1016/j.ahj.2007.08.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBenzenesulfonatesCardiac CatheterizationCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleElectrocardiographyFemaleFollow-Up StudiesHumansInfusions, IntravenousMaleMiddle AgedMyocardial InfarctionPiperazinesProbabilityReference ValuesRisk AssessmentSalvage TherapyStroke VolumeSurvival RateTreatment OutcomeVentricular Function, LeftConceptsPrimary percutaneous coronary interventionLeft ventricular ejection fractionST-elevation myocardial infarctionPrimary PCIMCC-135Percutaneous coronary interventionAcute myocardial infarctionInfarct sizeMyocardial infarctionDay 5Coronary interventionClinical outcomesCalcium overloadPreservation of LVEFAcute ST-elevation myocardial infarctionEnd pointTarget populationComposite clinical outcomeLeft Ventricular SalvagePlacebo-controlled studyPrimary end pointSecondary end pointsLow-dose groupVentricular ejection fractionHigh-dose group
2005
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study
Jang I, Pettigrew V, Picard M, Kowey P, Demmel V, Zile M, Tatsuno J, Wackers F, Hibberd M. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study. Journal Of Thrombosis And Thrombolysis 2005, 20: 147-153. PMID: 16261287, DOI: 10.1007/s11239-005-3267-4.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAngioplasty, Balloon, CoronaryBenzenesulfonatesCalciumDouble-Blind MethodEchocardiographyHumansMaleMiddle AgedMuscle CellsMyocardial InfarctionMyocardial Reperfusion InjuryNecrosisPiperazinesRadiographyTomography, Emission-Computed, Single-PhotonVentricular Function, LeftConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionLeft Ventricular SalvageElevation myocardial infarctionPlacebo-controlled clinical trialMCC-135Percutaneous coronary interventionIntracellular calcium overloadMyocardial infarctionPost-myocardial infarctionVentricular functionCalcium overloadEVOLVE studyCoronary interventionAdjunct therapyInfarct sizeClinical trialsPrimary PCIAcute ST-elevation myocardial infarctionMI studiesVentricular ejection fractionSerum cardiac markersAcute myocardial infarctionEarly clinical studiesMyocardial infarction size
2004
Cardiac Abnormalities in Diabetic Patients With Neuropathy
Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac Abnormalities in Diabetic Patients With Neuropathy. Diabetes Care 2004, 27: 448-454. PMID: 14747227, DOI: 10.2337/diacare.27.2.448.Peer-Reviewed Original ResearchMeSH KeywordsAldehyde ReductaseBenzothiazolesCardiac OutputDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NeuropathiesDouble-Blind MethodEnzyme InhibitorsExercise TestFemaleHeartHeart Conduction SystemHeart RateHumansMaleMiddle AgedPhthalazinesPlacebosStroke VolumeThiazolesVentricular Function, LeftConceptsLeft ventricular ejection fractionDiabetic patientsARI treatmentCardiac outputStroke volumeCardiac abnormalitiesAldose reductase inhibitorExercise left ventricular ejection fractionAbnormal heart rate variabilityDiastolic peak filling rateAsymptomatic cardiac abnormalitiesGated radionuclide ventriculographyMaximal bicycle exercisePlacebo-treated subjectsDiastolic filling rateVentricular ejection fractionCoronary artery diseaseValvular heart diseasePeak filling rateExercise cardiac outputLV stroke volumeHeart rate variabilityBlinded treatmentInsulin useArtery disease
1996
Distortion of the Terminal Portion of the QRS on the Admission Electrocardiogram in Acute Myocardial Infarction and Correlation With Infarct Size and Long-Term Prognosis (Thrombolysis In Myocardial Infarction 4 Trial)**This study was supported in part by a grant from SmithKline Beecham, Philadelphia, Pennsylvania.
Birnbaum Y, Kloner R, Sclarovsky S, Cannon C, McCabe C, Davis V, Zaret B, Wackers F, Braunwald E. Distortion of the Terminal Portion of the QRS on the Admission Electrocardiogram in Acute Myocardial Infarction and Correlation With Infarct Size and Long-Term Prognosis (Thrombolysis In Myocardial Infarction 4 Trial)**This study was supported in part by a grant from SmithKline Beecham, Philadelphia, Pennsylvania. The American Journal Of Cardiology 1996, 78: 396-403. PMID: 8752182, DOI: 10.1016/s0002-9149(96)00326-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngina PectorisCardiac Output, LowCoronary AngiographyCreatine KinaseDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionPatient AdmissionPrognosisRecurrenceRetrospective StudiesStroke VolumeSurvival RateTechnetium Tc 99m SestamibiThrombolytic TherapyTreatment OutcomeVentricular Function, LeftConceptsAcute myocardial infarctionLong-term prognosisAnterior acute myocardial infarctionCreatine kinase releaseInfarct sizeMyocardial infarctionMyocardial infarction (TIMI) 4 trialAnterior AMI patientsOne-year mortalityCoronary angiographic findingsLarger infarct sizeVentricular ejection fractionAdmission electrocardiogramHospital mortalityPrevious anginaSestamibi defectsAngiographic findingsBaseline characteristicsEjection fractionHeart failureAMI patientsClinical outcomesQRS distortionPatientsEnd pointComparison of Nifedipine GITS and Hydrochlorothiazide in the Management of Elderly Patients with Stage I–III Diastolic Hypertension*
Dey H, Soufer R, Hoffer P, Wackers F, Black H. Comparison of Nifedipine GITS and Hydrochlorothiazide in the Management of Elderly Patients with Stage I–III Diastolic Hypertension*. American Journal Of Hypertension 1996, 9: 598-606. PMID: 8783785, DOI: 10.1016/0895-7061(96)00168-9.Peer-Reviewed Original ResearchConceptsNifedipine gastrointestinal therapeutic systemGastrointestinal therapeutic systemDiastolic blood pressureBlood pressureDiastolic hypertensionStage IVentricular massCardiovascular functionTreatment differencesGoal diastolic blood pressureSignificant blood pressure reductionWeek placebo washout phasePlacebo washout phaseWeek maintenance phaseBlood pressure reductionGoal blood pressureDiastolic filling rateRenal blood flowGlomerular filtration rateLeft ventricular massBlood urea nitrogenShort-term therapyAdverse side effectsSignificant adverse effectsDiuretic therapy
1988
Oral Terbutaline Augments Cardiac Performance in Chronic Obstructive Pulmonary Disease
Chan C, Loke J, Snyder P, Wackers F, Mattera J, Matthay R. Oral Terbutaline Augments Cardiac Performance in Chronic Obstructive Pulmonary Disease. The American Journal Of The Medical Sciences 1988, 296: 33-38. PMID: 3044105, DOI: 10.1097/00000441-198807000-00007.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseVentricular ejection fractionSubmaximal steady-state exerciseOral terbutalineSteady-state exerciseEjection fractionPulmonary diseaseSevere chronic obstructive pulmonary diseaseLeft ventricular ejection fractionFirst-pass radionuclide angiographySystolic pump performancePlacebo-controlled trialState exerciseExpiratory volumeBlood pressureCardiopulmonary effectsPlacebo dayHemodynamic measurementsVital capacityRadionuclide angiographyCardiac functionSubmaximal exerciseCardiac performanceHeart rate